GeoVax Labs logo

GeoVax Labs

Stock
Stock
ISIN: US3736786068
Ticker: GOVX
US3736786068
GOVX

Price

Price

Frequently asked questions

What is GeoVax Labs's market capitalization?

The market capitalization of GeoVax Labs is $24.63M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for GeoVax Labs?

GeoVax Labs's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$9.207. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for GeoVax Labs's stock?

Currently, 2 analysts cover GeoVax Labs's stock, with a consensus target price of $72.00. Analyst ratings provide insights into the stock's expected performance.

What is GeoVax Labs's revenue over the trailing twelve months?

Over the trailing twelve months, GeoVax Labs reported a revenue of $3.09M.

What is the EBITDA for GeoVax Labs?

GeoVax Labs's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$24.40M. EBITDA measures the company's overall financial performance.

What is the free cash flow of GeoVax Labs?

GeoVax Labs has a free cash flow of -$27.24M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of GeoVax Labs's stock?

The 5-year beta for GeoVax Labs is 3.23. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does GeoVax Labs have, and what sector and industry does it belong to?

GeoVax Labs employs approximately 17 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of GeoVax Labs's shares?

The free float of GeoVax Labs is 9.39M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$24.63M

5Y beta

 
3.23

EPS (TTM)

 
-$9.207

Free Float

 
9.39M

Revenue (TTM)

 
$3.09M

EBITDA (TTM)

 
-$24.40M

Free Cashflow (TTM)

 
-$27.24M

Pricing

52W span
$1.09$11.18

Analyst Ratings

The price target is $72.00 and the stock is covered by 2 analysts.

Buy

2

Hold

0

Sell

0

Information

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

17

Biotechnology & Drugs

Health Care

Identifier

ISIN

US3736786068

Primary Ticker

GOVX
Join the conversation